Johnson & Johnson Announces Phase 2B Data From Two Studies Evaluating The JNJ-4804 Therapy Targeting Both Interleukin-23 And Tumor Necrosis Factor-Alpha In Patients With Moderately To Severely Active Ulcerative Colitis Or Crohn's Disease

The late-breaking presentations from the DUET-UC and DUET-CD studies were among the 32 company-sponsored abstracts being presented at Digestive Disease Week (DDW) 2026

JNJ-4804 demonstrated highest rates of clinical and endoscopic outcomes compared to golimumab and guselkumab in patients with ulcerative colitis or Crohn's disease who have had inadequate response to two or more systemic therapy classes

JNJ-4804 is the first and only fixed dose co-antibody designed to deliver molecular synergy in IBD by blocking the complementary IL-23 and TNF pathways

Data from Phase 2b DUET studies show potential to address a critical unmet need and support advancement to Phase 3 trials